Amyotropic Lateral Sclerosis (ALS) clinical trials at University of California Health
23 in progress, 11 open to eligible people
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons with Tetraplegia
““Turn thoughts into action” for people living with paralysis”
open to eligible people ages 18-80
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
at UC Davis
ECoG BMI for Motor and Speech Control
open to eligible people ages 21 years and up
Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.
at UCSF
BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
open to eligible people ages 18-80
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to…
at UC Davis
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
open to eligible people ages 10 years and up
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
at UCSD
PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
open to eligible people ages 18-80
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of…
at UCSF
Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
open to eligible people ages 18 years and up
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending…
at UC Irvine
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium…
at UCLA UCSD UCSF
ASSESS ALL ALS Study
open to eligible people ages 18 years and up
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium…
at UC Irvine UCSD UCSF
Clinical Procedures to Support Research in ALS
open to eligible people ages 18 years and up
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
at UC Irvine
PREVENT ALL ALS Study
open to eligible people ages 18 years and up
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium…
at UC Irvine UCSD UCSF
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
open to eligible people ages 18 years and up
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research…
at UCSD
Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Sorry, in progress, not accepting new patients
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to…
at UC Irvine
BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the…
at UCSD
of Ranolazine in ALS
Sorry, not currently recruiting here
The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
at UCSF
Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
at UCSD
HEALEY ALS Platform Trial - Master Protocol
Sorry, in progress, not accepting new patients
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
at UC Irvine UCSF
AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Sorry, in progress, not accepting new patients
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
at UC Irvine
Intermuscular Coherence as a Biomarker for ALS
Sorry, not currently recruiting here
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when…
at UC Irvine
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Sorry, accepting new patients by invitation only
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP),…
at UCSD
Pridopidine Expanded Access Program
Sorry, not accepting new patients
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
at UC Irvine UCSD
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Sorry, in progress, not accepting new patients
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be…
at UC Davis UCLA UCSF
RAPA-501 Therapy of ALS Expanded Access Protocol
Sorry, not accepting new patients
RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 T stem cells in patients living with amyotrophic lateral sclerosis (pwALS).
at UC Irvine UCSF
Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
Sorry, not accepting new patients
The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS). No formal clinical hypotheses are being evaluated with concurrent controls.…
at UC Irvine
Our lead scientists for Amyotropic Lateral Sclerosis (ALS) research studies include Laura Rosow, M.D. Karunesh Ganguly, MD, PhD Sergey Stavisky, Ph.D. Mario F. Mendez, MD, PhD Vinil Shah John Ravits, MD.
Last updated: